** Kombiglyze™ XR (saxagliptin and metformin HCl extended-release) 2.5 mg/1000 mg 60 Tablets. Once A Day.
** For Oral Use.
Each tablet contains:
Saxagliptin hydrochloride (anhydrous) 2.79 mg equivalent to Saxagliptin 2.5 mg and
Metformin hydrochloride 1000 mg
** Indications and Usage:
Kombiglyze XR is a combination of saxagliptin, a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.
Limitation of Use:
– Not for treatment of type 1 diabetes or diabetic ketoacidosis
– Has not been studied in patients with a history of pancreatitis.
** Do not crush, cut, or chew tablets. Tablets must be swallowed whole.
** See accompanying package insert for indications and dosing information.
** Store below 30 degrees C.
Keep out of reach of children.
** Manufactured by:
Bristol-Myers Squibb Company
4601 Highway 62 East Mount Vernon, Indiana 47620, USA
Bristol-Myers Squibb and AstraZeneca
Kombiglyze is a trademark of Bristol-Myers Squibb Company.
Marketing Authorisation Holder is Bristol-Myers Squibb, Princeton, NJ 08453, USA
استيراد : الشركة المتحدة للتوزيع ومستلزمات الصيدليات